MLYBY yields 4.15% · PFE yields 6.13%● Live data
📍 MLYBY pulled ahead of the other in Year 1
Combined, MLYBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MLYBY + PFE for your $10,000?
Malayan Banking Berhad provides commercial banking and related financial products and services for individuals, small and medium enterprises, retail and corporate customers, and financial institutions primarily in Malaysia, Singapore, and Indonesia. The company operates through three segments: Group Community Financial Services, Group Global Banking, and Group Insurance and Takaful. It offers savings and fixed deposits, and current and money market accounts; and housing and personal loans, project financing, overdrafts, and trade financing, as well as remittance service. The company also offers credit cards; bancassurance products; hire purchase, unit trust, cash management, custodian, and trustee services; and treasury activities and services, including foreign exchange, money market, derivatives, and trading of capital market. In addition, it provides investment banking and securities broking services; corporate advisory, bond and equity issuance, syndicated acquisition advisory, debt restructuring advisory, and share and futures dealings; and asset and fund management services, including a range of conventional and Islamic investment solutions. Further, the company underwrites general and life insurance businesses, offshore investment life insurance business, and general and family takaful products; and offers offshore banking, property leasing and trading, nominee, property investment, IT shared and development, financial and investment advisory, money lending, private equity investments, research, and leasing and factoring services. The company operates a network of approximately 2,200 branches in 20 countries internationally. Malayan Banking Berhad was incorporated in 1960 and is headquartered in Kuala Lumpur, Malaysia.
Full MLYBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.